With a market cap of $56.5 billion, Corteva, Inc. (CTVA) is an agriculture company, serving markets across North America, Latin America, Asia Pacific, Europe, the Middle East, and Africa. The company operates through two main segments: Seed and Crop Protection, developing advanced seed genetics, traits, and crop protection products to help improve farm productivity and resilience.
Companies worth more than $10 billion are generally labeled as “large-cap” stocks and Corteva fits this criterion perfectly. It also provides herbicides, insecticides, nitrogen stabilizers, and digital farming solutions that support farmers in optimizing crop yield and profitability.
Shares of the Indianapolis, Indiana-based company have decreased nearly 6% from its 52-week high of $90.97. Corteva's shares have increased nearly 13% over the past three months, outpacing the State Street Materials Select Sector SPDR ETF's (XLB) 1.2% rise over the same time frame.
CTVA stock is up 26.4% on a YTD basis, outperforming XLB’s 13.3% gain. Longer term, shares of the agricultural technology company have returned 16.9% over the past 52 weeks, compared to XLB's 13.5% return over the same time frame.
The stock has been trading above its 50-day moving average since late August.
Corteva has outperformed over the past year due to stronger execution, improved business visibility, and resilient fundamentals, particularly in its seed business. The planned separation into two focused businesses has also highlighted the higher-growth, higher-margin seed operations, while improving expectations for crop-protection pricing and lower separation costs have supported the earnings outlook. More recently, analysts raised its 2026 - 2028 EPS forecasts and expect substantial long-term growth from seed pricing, licensing income, innovation and cost savings, reinforcing the company’s stronger earnings trajectory.
In comparison, rival CF Industries Holdings, Inc. (CF) has surpassed CTVA stock. Shares of CF Industries have surged 62.3% over the past 52 weeks and 82.3% on a YTD basis.
Despite CTVA’s outperformance relative to the sector, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from 20 analysts, and the mean price target of $91.90 is a premium of 8.4% to current levels.
